Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq of brain metastatic breast cancer cell lines after knockout of lipid metabolism genes using CRISPR/Cas9 gene editing

ABSTRACT: Brain metastasis is one of the lethal causes of breast cancer. Here we identified an altered lipid metabolism state to be associated with brain metastatic potential of breast cancer cell lines. To investigate the mechanism, we knocked out genes mediating this altered state and examined transcriptomic changes. The results revealed that these genes confer cells a state with increased lipid and cholesterol biosynthesis and that resembles the lipid metabolite state seen in the brain. These findings revealed an unappreciated machinery that cancer cells adopt for their increased adaptability to the brain microenvironment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE148372 | GEO | 2020/06/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MeRIP-sequencing for dynamic epi-transcriptomic landscape mapping with disease progression in ER-positive breast cancer

Project description:Advanced breast cancer is characterised by enhanced tumour adaptability to therapeutic pressure and the metastatic microenvironment. Targeting epi-transcriptomic modulators may reverse cellular adaptability, offering new therapeutic strategies to treat metastatic disease. This study looks into the dynamic adaptations that occur in cancer cells in response to therapeutic pressure and metastatic evolution by profiling mRNA epi-transcriptomic modifications in models of disease progression. ER positive (ER+) cell models were used to represent progressive breast cancer, MCF7 (endocrine sensitive), LY2 (endocrine resistant) and T347 (derived from an ER-positive, treatment resistant brain metastatic patient tumour) cells. MeRIP sequencing was undertaken to determine genome-wide RNA methylated regions.

2023-05-16 | GSE176533 | GEO

RNA-sequencing for dynamic epi-transcriptomic landscape mapping with disease progression in ER-positive breast cancer

Project description:Advanced breast cancer is characterised by enhanced tumour adaptability to therapeutic pressure and the metastatic microenvironment. Transcriptome differences in three ER positive (ER+) cell models are uncovered through this RNA-seq analysis of MCF7 (endocrine sensitive), LY2 (endocrine resistant) and T347 (derived from an ER-positive, treatment resistant brain metastatic patient tumour) cells.

2023-05-16 | GSE176534 | GEO

Investigating the altered brain metastatic transcriptome in breast cancer

Project description:Investigating the altered brain metastatic transcriptome in breast cancer

| PRJNA726554 | ENA

Investigating the altered brain metastatic transcriptome in breast cancer

Project description:Investigating the altered brain metastatic transcriptome in breast cancer

| PRJNA766683 | ENA

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

Project description:CDK4/6 inhibitor, Palbociclib, has shown a high success in breast cancer subtypes however it is often accompanied by a dependency on mutation status of cell lines. Consequently, there has been speculation on the breast cancer subtypes which should be offered treatment with specific CDK4/6 inhibitors and the response that can be expected. A common observation has been the induction of a cell programme known as "senescence" whereby cells experience a complete halt in mitosis, however, remaining metabolically active. Therapy-induced senescence markers and its effect on the tumour microenvironment as well as the diversity of this cell state remain unappreciated. In the following proteomics, phosphoproteomics and secretome datasets we focus on MDA-MB-231 cells, a triple negative cell line, to better understand the senescence-like cell state which arises after treatment. Ultimately, the dataset encompasses the population that arises upon Palbociclib treatment and highlights potential signatures and biomarkers of the cell state which could provide information on the use of CDK4/6 inhibitors in triple negative breast cancer subtypes.

2022-01-28 | PXD030407 | Pride

Inhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer.

Project description:CDK4/6 inhibition is the standard of care for estrogen receptor positive (ER+) breast cancer, although cytostasis is frequently observed, and new treatment strategies that enhance efficacy are required. We performed a genome-wide CRISPR screen to identify genetic determinants of CDK4/6 inhibitors sensitivity. Multiple genes involved in oxidative stress and ferroptosis modulated palbociclib sensitivity. Depletion or inhibition of GPX4 increased sensitivity to palbociclib in ER+ breast cancer models, and sensitised triple negative breast cancer models to palbociclib, with GPX4 null xenografts being highly sensitive to palbociclib. Palbociclib induced oxidative stress and disordered lipid metabolism with lipid peroxidation, leading to a ferroptosis-sensitive state. Lipid peroxidation relied on a peroxisome AGPAT3-dependent pathway in ER+ breast cancer models, rather than the classical ACSL4 pathway. Our data demonstrate that CDK4/6 inhibition creates vulnerability to ferroptosis that could be exploited through combination with GPX4 inhibitors, enhancing sensitivity to CDK4/6 inhibition in breast cancer.

2023-06-20 | PXD043133 | Pride

ChIP-chip of 6 chromatin marks (FAIRE, H3K4me1, H3K4me3, H3K27me3, H3R17me2, H3AZAce) in breast cancer cell line MCF7

Project description:Altered gene expression patterns in human diseases reflect perturbations in the transcriptional networks that regulate cellular state. In breast cancer, Nuclear Receptors (NRs) play a prominent role in governing gene expression. NRs have prognostic utility and are therapeutically important targets. Here we describe a complete regulatory map for twenty-four NR proteins that are expressed in the breast cancer cell line MCF-7, as well as fourteen additional breast cancer associated transcription factors (TFs) and six key chromatin state markers. Input DNA was used as control against all 6 Chromatin ChIPchip samples grown in complete medium. All samples are done in triplicates.

2013-01-01 | E-GEOD-42617 | biostudies-arrayexpress

Gene expression in breast cancer cell with shYTHDF3

Project description:Knocking down YTHDF3 in breast cancer cells resulted in an altered gene expression profile N6-methyl-adenosine (m6A) is the most prevalent internal chemical modification in eukaryotic messenger RNAs and emerging as a critical mRNA chemical mark that mediates post-transcriptional gene expression regulation. YTHDF3 facilitates translation and decay of m6A-modified mRNAs. However, the role for YTHDF3 protein in breast cancer brain metastasis remain to be elucidated. We found that YTHDF3 is overexpressed in brain metastasis of breast cancer cells. Our study will characterize the expression profiling in YTHDF3 silencing breast cancer cells compared to shControl breast cancers cells. The objectives are to identify expression profiles that are specific to shYTHDF3 breast cancer cell to identify new the signaling pathway of YTHDF3 for brain metastasis of breast cancer cells.

2020-09-30 | GSE129945 | GEO

Gene expression in breast cancer cell with shYTHDF3 [mouse]

2020-09-30 | GSE129946 | GEO

Project description:Rewiring of lipid metabolism is essential for cell state transitions in breast cancer

| PRJNA480163 | ENA